STOCK TITAN

QuidelOrtho Corporation - QDEL STOCK NEWS

Welcome to our dedicated news page for QuidelOrtho Corporation (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on QuidelOrtho Corporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect QuidelOrtho Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of QuidelOrtho Corporation's position in the market.

Rhea-AI Summary
QuidelOrtho Corporation (Nasdaq: QDEL) to Participate in Evercore ISI Conference on November 30, 2023. The company's President and CEO, Douglas Bryant, will join a fireside chat at 9:10 a.m. ET. The live webcast and replay will be accessible on the 'Events & Presentations' section of QuidelOrtho’s Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
conferences
-
Rhea-AI Summary
QuidelOrtho Corporation reported third-quarter revenue of $744 million, with strong respiratory demand and growth in non-respiratory businesses. Adjusted diluted earnings per share were $0.90, and adjusted EBITDA was $169 million with a margin of 23%. The company paid down $52 million of debt during the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
-
Rhea-AI Summary
Global Lyme Alliance produces chronic Lyme PSA with generous sponsorship from QuidelOrtho
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
Rhea-AI Summary
QuidelOrtho reports strong preliminary unaudited revenue results for Q3 2023, driven by higher respiratory product sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.17%
Tags
-
Rhea-AI Summary
QuidelOrtho receives CLIA Waiver for its Sofia 2 SARS Antigen+ FIA test, the first rapid antigen test for COVID-19 to receive this clearance. The test can now be used in CLIA-waived point-of-care settings, expanding its use. The Sofia 2 system provides an automated result in just 10 minutes, a 33% reduction in processing time. QuidelOrtho's commitment to innovation and accessibility is further demonstrated by this achievement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none
-
Rhea-AI Summary
QuidelOrtho to participate in Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.27%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
partnership
Rhea-AI Summary
QuidelOrtho Corporation (Nasdaq: QDEL) will report its Q2 2023 financial results on August 8, 2023, followed by a conference call. Interested parties can access the call and presentation materials on the Investor Relations page of the company's website. A replay will also be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
conferences earnings
QuidelOrtho Corporation

Nasdaq:QDEL

QDEL Rankings

QDEL Stock Data

2.82B
50.57M
1.4%
100.46%
3.37%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
San Diego

About QDEL

QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.